Labcorp (LH) stock trades up, here is why

Labcorp Holdings (NYSE:LH), a prominent player in healthcare diagnostics, saw its stock price surge by 10.3% during the afternoon trading session following the release of its third-quarter earnings, which exceeded analysts' expectations. The company also revised its full-year revenue projections upward.

In a press release, Labcorp announced that its revenue for the third quarter reached $3.81 billion, marking an increase from $3.56 billion in the same quarter last year. This figure surpassed the consensus forecast of $3.76 billion set by analysts.

Adjusted earnings per share (EPS) climbed to $4.78, up from $4.18 in the prior-year quarter, also exceeding the expected EPS of $4.65. The diluted earnings per share rose to $3.22 from $3.12. Along with these quarterly results, Labcorp updated its guidance for the full year 2026, projecting enterprise revenue growth between 5.9% and 6.7%, and adjusted EPS in the range of $18.30 to $18.70.

The recent jump in Labcorp's stock is noteworthy, as the company's shares have been relatively stable over the past year, with no fluctuations exceeding 5%. Such a significant increase indicates that this news has notably shifted market perceptions about the company.

In the past year, the most significant movement in Labcorp's stock occurred about a year ago when it rose by 3.1%. This increase was attributed to a broader market shift where investors moved away from growth-oriented technology stocks and gravitated towards value stocks amid concerns regarding valuations. During this time, the tech-heavy Nasdaq index experienced a slight decline of 0.2%, while the Dow Jones Industrial Average gained ground.

This pivot away from technology stocks was influenced by various negative developments in the AI sector. CoreWeave, an AI cloud service provider, reported disappointing guidance, and Nvidia's stock faced pressure following SoftBank's decision to divest its stake. These events contributed to a downturn in the AI sector, affecting related companies such as Micron and Oracle.

As capital exited the tech sector, investors sought refuge in more stable "defensive" stocks, leading to increased buying interest in healthcare companies like Merck, Amgen, and Johnson & Johnson, which in turn bolstered the Dow's performance.

Since the beginning of the year, Labcorp's stock has surged by 45.4%, reaching a new 52-week high of $365.79 per share. For investors who purchased $1,000 worth of Labcorp shares five years ago, their investment would now be valued at approximately $1,282.

In addition to Labcorp's positive performance, the market is also observing other emerging platforms that are reportedly growing at rates three times faster than major companies like Amazon, Google, and PayPal. These platforms are said to be following a similar strategy: targeting overlooked markets, establishing a strong competitive edge, and scaling operations to achieve significant market presence. Early investors in these platforms may potentially see substantial returns, akin to those who invested early in Amazon.